A group of Japanese researchers announced on Friday that it has caused pluripotent stem cell transplantation (iPS) in the brain of a patient suffering from Parkinson's disease, the first test of its kind in the world.
The University of Kyoto 2.4 million iPS cells were injected – capable of producing any type of cell – on the left part of the brain during a three hour operation in October.
The man, aged about 50, was well treated and will remain under surveillance for two years, Kyoto University said in a statement.
If a problem arises in the next six months, researchers will implant 2.4 million additional cells, this time to the right of the brain.
These iPS cells from healthy donors are supposed to grow in dopamine-producing neurons, a neurotransmitter involved in motor control.
The University of Kyoto announced in July that it would do one clinical trial with seven individuals aged between 50 and 69 years.
The Parkinson's disease is characterized by degeneration of neurons, With symptoms that gradually deteriorate, such as tremor, muscle stiffness and loss of body's ability to move.
Read here: Parkinson's disease may come from the annex
It affects more than ten million people in the world, according to the American Parkinson's Disease Foundation. In the In Colombia there are more than 220,000 people with the disease, according to the Colloquial Union of Neurology. Currently available treatments "improve symptoms without slowing down disease progression," the institute explains.
New investigations aim to overthrow the evil. Prior to clinical trial in humans, an experiment was conducted with monkeys with human stem cells which allowed the improvement of the kinetic ability of primates affected by a type of Parkinson, according to a study published in late August 2017 in the journal Nature.
For two years the survival level of the transplanted cells was closely monitored by infusion into the primary brain and no tumor was detected.
Induced pluripotent stem cells (iPS) are adult cells that have declined in their near-fetal condition to produce four genes (usually inactive in adults). This genetic manipulation returns the ability to produce any cell depending on where the body is transplanted.
The use of iPS cells does not create significant moral problems, as opposed to stem cells derived from human embryos.